A citation-based method for searching scientific literature


List of co-cited articles
12 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition.
Issei Tomita, Shinji Kume, Sho Sugahara, Norihisa Osawa, Kosuke Yamahara, Mako Yasuda-Yamahara, Naoko Takeda, Masami Chin-Kanasaki, Tatsuroh Kaneko, Eric Mayoux,[...]. Cell Metab 2020
81
60

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
379
40

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
480
40


Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo-Controlled Trial.
Anne Zanchi, Michel Burnier, Marie-Eve Muller, Arlène Ghajarzadeh-Wurzner, Marc Maillard, Nicolas Loncle, Bastien Milani, Nathalie Dufour, Olivier Bonny, Menno Pruijm. J Am Heart Assoc 2020
24
40

SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease.
So Ra Kim, Sang-Guk Lee, Soo Hyun Kim, Jin Hee Kim, Eunhye Choi, Wonhee Cho, John Hoon Rim, Inhwa Hwang, Chan Joo Lee, Minyoung Lee,[...]. Nat Commun 2020
109
40

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors.
Subodh Verma, Sonia Rawat, Kim L Ho, Cory S Wagg, Liyan Zhang, Hwee Teoh, John E Dyck, Golam M Uddin, Gavin Y Oudit, Eric Mayoux,[...]. JACC Basic Transl Sci 2018
173
40

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.
Mikhail Kosiborod, Kåre I Birkeland, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Marit E Jørgensen, Eric T Wittbrodt,[...]. Diabetes Obes Metab 2018
57
40

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Annayya R Aroor, Nitin A Das, Andrea J Carpenter, Javad Habibi, Guanghong Jia, Francisco I Ramirez-Perez, Luis Martinez-Lemus, Camila M Manrique-Acevedo, Melvin R Hayden, Cornel Duta,[...]. Cardiovasc Diabetol 2018
75
40

The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.
Yusuke Nakatsu, Hiroki Kokubo, Batmunkh Bumdelger, Masao Yoshizumi, Takeshi Yamamotoya, Yasuka Matsunaga, Koji Ueda, Yuki Inoue, Masa-Ki Inoue, Midori Fujishiro,[...]. Int J Mol Sci 2017
45
40

IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.
Hong Sun, Pouya Saeedi, Suvi Karuranga, Moritz Pinkepank, Katherine Ogurtsova, Bruce B Duncan, Caroline Stein, Abdul Basit, Juliana C N Chan, Jean Claude Mbanya,[...]. Diabetes Res Clin Pract 2022
148
40

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
40

Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure.
Salva R Yurista, Timothy R Matsuura, Herman H W Silljé, Kirsten T Nijholt, Kendra S McDaid, Swapnil V Shewale, Teresa C Leone, John C Newman, Eric Verdin, Dirk J van Veldhuisen,[...]. Circ Heart Fail 2021
32
20

Myocardial ketone body utilization in patients with heart failure: The impact of oral ketone ester.
Luca Monzo, Kamil Sedlacek, Katarina Hromanikova, Lucie Tomanova, Barry A Borlaug, Antonin Jabor, Josef Kautzner, Vojtech Melenovsky. Metabolism 2021
14
20

mTOR Signaling in Growth, Metabolism, and Disease.
Robert A Saxton, David M Sabatini. Cell 2017
20


Histone Deacetylase Inhibitors and Diabetic Kidney Disease.
Mitchell J Hadden, Andrew Advani. Int J Mol Sci 2018
39
20


Mitochondrial energetics in the kidney.
Pallavi Bhargava, Rick G Schnellmann. Nat Rev Nephrol 2017
407
20



SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.
Emily Brown, Hiddo J L Heerspink, Daniel J Cuthbertson, John P H Wilding. Lancet 2021
41
20

SGLT2-inhibitors; more than just glycosuria and diuresis.
Amir Fathi, Keeran Vickneson, Jagdeep S Singh. Heart Fail Rev 2021
12
20

Targeting Mitochondria-Inflammation Circuit by β-Hydroxybutyrate Mitigates HFpEF.
Yan Deng, Maodi Xie, Qian Li, Xuewen Xu, Wei Ou, Yabing Zhang, Haitao Xiao, Hai Yu, Yanyi Zheng, Yu Liang,[...]. Circ Res 2021
69
20


Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Volker Vallon, Subodh Verma. Annu Rev Physiol 2021
38
20


Ketone Body Infusion Increases Circulating Erythropoietin and Bone Marrow Glucose Uptake.
Katrine M Lauritsen, Esben Søndergaard, Mads Svart, Niels Møller, Lars C Gormsen. Diabetes Care 2018
4
25

Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.
Ralph A DeFronzo, W Brian Reeves, Alaa S Awad. Nat Rev Nephrol 2021
68
20


HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes.
Jenny Y Y Ooi, Natasha K Tuano, Haloom Rafehi, Xiao-Ming Gao, Mark Ziemann, Xiao-Jun Du, Assam El-Osta. Epigenetics 2015
78
20


Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists.
Francesco Prattichizzo, Paola de Candia, Antonio Ceriello. Metabolism 2021
9
20

Cardiac Energy Metabolism in Heart Failure.
Gary D Lopaschuk, Qutuba G Karwi, Rong Tian, Adam R Wende, E Dale Abel. Circ Res 2021
60
20

Sodium-Glucose Cotransporter Type 2 (SGLT-2) Inhibitors and Ketogenesis: the Good and the Bad.
Preethika Ekanayake, Christopher Hupfeld, Sunder Mudaliar. Curr Diab Rep 2020
8
20



Kidney hypoxia, attributable to increased oxygen consumption, induces nephropathy independently of hyperglycemia and oxidative stress.
Malou Friederich-Persson, Erik Thörn, Peter Hansell, Masaomi Nangaku, Max Levin, Fredrik Palm. Hypertension 2013
106
20

A Ketogenic Diet Extends Longevity and Healthspan in Adult Mice.
Megan N Roberts, Marita A Wallace, Alexey A Tomilov, Zeyu Zhou, George R Marcotte, Dianna Tran, Gabriella Perez, Elena Gutierrez-Casado, Shinichiro Koike, Trina A Knotts,[...]. Cell Metab 2017
194
20

Determinants of kidney oxygen consumption and their relationship to tissue oxygen tension in diabetes and hypertension.
Peter Hansell, William J Welch, Roland C Blantz, Fredrik Palm. Clin Exp Pharmacol Physiol 2013
156
20

Loss of Metabolic Flexibility in the Failing Heart.
Qutuba G Karwi, Golam M Uddin, Kim L Ho, Gary D Lopaschuk. Front Cardiovasc Med 2018
149
20

Starvation in man.
G F Cahill. N Engl J Med 1970
630
20


Increased renal metabolism in diabetes. Mechanism and functional implications.
A Körner, A C Eklöf, G Celsi, A Aperia. Diabetes 1994
142
20

Role for TNF in atherosclerosis? Lessons from autoimmune disease.
Gayle E McKellar, David W McCarey, Naveed Sattar, Iain B McInnes. Nat Rev Cardiol 2009
202
20

Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Roni Nielsen, Niels Møller, Lars C Gormsen, Lars Poulsen Tolbod, Nils Henrik Hansson, Jens Sorensen, Hendrik Johannes Harms, Jørgen Frøkiær, Hans Eiskjaer, Nichlas Riise Jespersen,[...]. Circulation 2019
138
20

High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection.
Hiroyuki Umino, Kazuhiro Hasegawa, Hitoshi Minakuchi, Hirokazu Muraoka, Takahisa Kawaguchi, Takeshi Kanda, Hirobumi Tokuyama, Shu Wakino, Hiroshi Itoh. Sci Rep 2018
71
20

Erasers of histone acetylation: the histone deacetylase enzymes.
Edward Seto, Minoru Yoshida. Cold Spring Harb Perspect Biol 2014
821
20

Inflammasomes: mechanism of action, role in disease, and therapeutics.
Haitao Guo, Justin B Callaway, Jenny P-Y Ting. Nat Med 2015
20



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.